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Abstract
The rapidly increasing amount of public data in chemistry and biology provides new opportunities for large-scale data
mining for drug discovery. Systematic integration of these heterogeneous sets and provision of algorithms to data mine the
integrated sets would permit investigation of complex mechanisms of action of drugs. In this work we integrated and
annotated data from public datasets relating to drugs, chemical compounds, protein targets, diseases, side effects and
pathways, building a semantic linked network consisting of over 290,000 nodes and 720,000 edges. We developed a
statistical model to assess the association of drug target pairs based on their relation with other linked objects. Validation
experiments demonstrate the model can correctly identify known direct drug target pairs with high precision. Indirect drug
target pairs (for example drugs which change gene expression level) are also identified but not as strongly as direct pairs.
We further calculated the association scores for 157 drugs from 10 disease areas against 1683 human targets, and measured
their similarity using a 157|1683 score matrix. The similarity network indicates that drugs from the same disease area tend
to cluster together in ways that are not captured by structural similarity, with several potential new drug pairings being
identified. This work thus provides a novel, validated alternative to existing drug target prediction algorithms. The web
service is freely available at: http://chem2bio2rdf.org/slap.
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Introduction
Understanding the interaction of drugs with multiple targets can
identify potential side effects and toxicities [1–3], as well as
possible new applications of existing drugs [4–8]. Many efforts
have been made to integrate drug-target interactions in a large
scale [9–12]. A variety of computational approaches have been
previously explored for predicting drug-target interactions,
including molecular docking [3,13,14], ligand-based predictive
models [15,16], phenotype similarity (side effect similarity [17] or
gene expression profile similarity [18]) and chemical ontology
similarity [19]. Some similarity measurements have been com-
bined to elucidate drug targets [20]. Network analysis based on the
topology of known drug target network has also been utilized for
drug target prediction, but is currently limited to small data sets
[21,22].
Recent advances in the Semantic Web [23] have enabled the
creation of large heterogeneous networks of experimental and
other data in life sciences (for example: Chem2Bio2RDF [24],
LODD [25], Bio2RDF [26], OpenPHACTS (http://openphacts.
org), linked life data (http://linkedlifedata.com) and Linked Open
Data (http://linkeddata.org)), where the nodes can include
physical and abstract entities (compounds, protein targets,
substructures, side effects, diseases, pathways, tissues, gene
ontology terms and so on), and the edges (or links) represent
various relations between objects such as drug-drug interactions,
and drug target interactions, protein-protein interactions and so
on. The ability to easily integrate heterogeneous datasets in a
meaningful fashion makes semantic technologies attractive,
although it is only recently that supporting technologies have
adequately matured to make them useful in the biological sciences:
in particular the advent of fast triple stores for data storage, the
SPARQL query language (http://www.w3.org/TR/rdf-sparql-
query/) for searching, and the OWL ontology language (http://
www.w3.org/TR/owl-features/) for the description of ontologies.
Despite remaining deficiencies which are being addressed in the
Semantic Web community (including difficulty weighting edges
and maintaining provenance information) there are now many
examples of successful use of semantics in the life sciences [27]. In
contrast to hyperlinked data, semantic linked data encodes explicit
meanings of nodes and links, allowing traversing from one node to
another via particular kinds of relationship. Prediction of links not
in the dataset, based on the existing links, is widely used in social
networking, in which it is assumed that two nodes are similar if
they share similar topology (e.g., a certain number of neighbors,
and similar shortest paths) [28–30]. For example, in a coauthor-
ship network, two authors are similar in terms of research interests
if they coauthor lots of papers, hence their potential collaboration
could be predicted (it should be noted that social networks
generally only deal with positive relationships; drug discovery data
is different in that negative relationships such as inactivity are
important).
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In this work, we sought to use such semantic methods to
integrate and annotate the data in relation to drug target
interaction, constructing a heterogeneous network composed by
over 290 k nodes and 720 k edges. We further developed a
statistical model called Semantic Link Association Prediction
(SLAP) to assess the association of drug target pairs and to predict
missing links. An association score is calculated based on the
topology and semantics of the neighborhood. We demonstrate that
SLAP can correctly identify known drug target pairs from random
pairs with high accuracy and can also identify indirect drug target
relations (e.g., the change of gene expression level). The
association scores of a drug against a set of targets constitute a
biological signature that allows assessing the similarity of drugs in
the context of the whole system. The resulting drug similarity
network clusters drugs from the same therapeutic indication in
ways not observed using chemical structure similarity, and can also
be used to identify potential new indications for existing drugs.
Results
Semantic linked data
The SLAP pipeline is shown in Figure 1. A heterogeneous
network consisting of 295,897 nodes and 727,997 edges was
constructed from 17 public data sources pertaining to drug target
interaction. Every node and edge was semantically annotated
using a systems chemical biology/chemogenomics ontology
previously developed in our labs [31]. The nodes were grouped
into 10 classes which are linked by 12 types (Figure 1b). A single
node is an instance of a corresponding class, for example: a node
for the drug Troglitazone (labeled as 5591 in Figure 2) is an
instance of class Chemical Compound. We term paths of nodes
and edges that share the same semantics (but different data) path
patterns - each path is an instance of a path pattern. Table 1 shows
6 path pattern examples between Drugs and Targets. In Figure 2,
the path from node 5591 (Troglitazone) to node PPARG
(Glitazone receptor) via ACSL4 (Long-chain-fatty-acid CoA ligase
4) and 446284 (Eicosapentaenoic acid) is an instance of the path
pattern 1 in Table 1. We can interpret this path as indicating
Troglitazone could bind to ACSL4 which shares compound
Eicosapentaenoic acid with target PPARG. With the assumption
that two nodes are associated if they link to at least one other node,
or their linked nodes are linked, their relations can be assessed by
the analysis of the links (or paths) between the two nodes [32]. The
strength of their relation in the network can be measured by the
distance, the number of shortest paths and other topological
properties between the two nodes. In our example of the
relationship between Troglitazone and target PPARG, several
paths provide ‘‘evidence’’ of a relationship: Troglitazone and
Rosiglitazone both are hypoglycemic drugs and the latter is the
ligand of PPARG; Troglitazone binds to ACSL4 which shares
pathway(PPAR signaling pathway), ligand (Eicosapentaenoic acid)
and GO term (response to nutrient) with PPARG. A total of 1684
paths (length lƒ3) belonging to 10 path patterns contribute to
their relation.
Pattern score distribution
Each path between two nodes may contribute to the relation
between them, but the degree of contribution varies depending on
path distance and the weight of the edges involved in the path. For
example, a gene ontology molecular function term (GO:0005515)
shared by proteins is not as informative as a binding term
(GO:0005488) in assessing the similarity of two proteins. Thus the
weight of the edge linking one protein node to the molecular
function node is lower than that linking to the binding node.
According to this observation, we developed a statistical model to
measure the weight of edges as well as the significance of paths (see
methods). The model takes into account the distance and the
weight of each edge, and renders a raw score indicating the
strength of each path. We found that the raw scores within the
same path pattern are normally distributed, while the mean and
standard deviation of patterns are different (Figure S1). Z scores
converted from raw scores based on pattern score distribution are
used to measure the contribution to the association: the higher the
z score, the more contribution the path has. The sum of z scores of
all paths is defined as association score indicating the association
strength of the drug target pair. The logarithm of association
scores of random drug target pairs fit to a normal distribution
(Figure S2), that enables calculation of the significance of a given
association score. For our Troglitazone & PPARG example, the p-
value is 9.06E-6, indicating a strong association.
Pattern importance
A low p-value between a drug-target pair indicates a strong
probability of association between the drug and target, but it does
not necessarily mean the drug and target would interact
biologically. Some patterns may be uninformative. We therefore
considered each pattern as a feature and assessed each feature
alone for its ability to identify drug-target pairs from random pairs
across the set. Table 1 lists three informative patterns and three
uninformative patterns along with ROC scores. The first two
patterns illustrate the drug likely interacts with a protein that
shares commonalities in terms of GO or ligand binding profile
with an existing target that the drug already is known to interact
with. The third pattern indicates that the drug likely interacts with
a protein with which another structural similar drug could
interact. As a result of this analysis, 12 ‘‘uninformative’’ patterns
were removed. The sum of z score of a given pair is the sum of z
scores of the paths belonging to the informative patterns.
Association scores of drug target pairs
We randomly selected 1000 known drug target pairs from
DrugBank and compared their association scores with 1000
random pairs of drugs and targets sampled from DrugBank. For
Author Summary
Modern drug discovery requires the understanding of
chemogenomics, the complex interaction of chemical
compounds and drugs with a wide variety of protein
target and genes in the body. A large amount of data
pertaining to such relationships exists in publicly-accessi-
ble datasets but it is siloed and thus impossible to use in
an integrated fashion. In this work we have integrated and
semantically annotated a large amount of public data from
a wide range of databases, including compound-gene,
drug-drug, protein-protein, drug-side effects and so on, to
create a complex network of interactions relating to
compounds and protein targets. We developed a statistical
algorithm called Semantic Link Association Prediction
(SLAP) for predicting ‘‘missing links’’ in this data network:
i.e. compound-target interactions for which there is no
experimental data but which are statistically probable
given the other relationships that exist in this set. We
present validation experiments which show this method
works with a high degree of accuracy, and also demon-
strate how it can be used to create a drug similarity
network to make predictions of new indications for
existing drugs.
Drug Target Association with Semantic Linked Data
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each drug target pair, their direct link was removed in the score
calculation so that their association is only determined by their
neighborhood properties. We thus aimed to test the ability of
SLAP to correctly identify ‘‘missing links’’ in the data, with the
assumption that this might be used, for instance, to profile a group
of compounds against an identified set of targets. As Figure 3
shows, random pairs have a broad range of scores, but most of
them are close to zero. Overall, real drug-target pairs have much
higher scores than random pairs (pv2:2E{16 using paired t test).
We also took all drug target pairs from DrugBank (in total 5607
pairs in which 4508 pairs have at least one path with length lƒ3).
We sampled the same number of random drug target pairs as
decoys to check the capability of identifying real drug target pairs
by SLAP. We compared SLAP with other link prediction methods
adopted in social network analysis [32]. The AUROC of SLAP is
0.92, outperforming other methods (i.e., the number of shortest
paths, and the number of valid paths)(Figure 4). As the ratio
between true drug target pairs versus random pairs decreases (e.g.,
ratio = 1/12), the ROC scores do not vary very much
(AUROC&0:92) and SLAP still performs much better than
others, although the precision goes down considerably (Figure S5).
Even when random pairs are 12 times more than positive pairs,
the precision still can reach 0.6 while recall is 0.7. In addition, we
noticed using the sum (or max or mean) of raw score of the shortest
path (without converting into z scores) performs as a random
choice, indicating the importance of introducing random samples.
Since several drug target prediction approaches reported that the
performances may vary among different target classes [33], we
grouped the drug target pairs into 5 classes (Enzyme, Membrane
Receptor, Ion Channel, Transporter and Transcription Factor),
and found that the score does not have any preference to a
particular target class, indicating SLAP is capable of treating
different classes of protein targets(Figure S4).
As far as we are aware, SLAP is the only large predictive
network model that has been applied to drug discovery data.
However other drug-target prediction methods have been the
subject of recent publications [7,17,34], and we thus sought to
consider how the effectiveness of SLAP compares with these
methods. We ran SLAP against 23 drug target pairs (including 15
aminergic G-protein-coupled receptors and 8 cross-boundary
targets) predicted and confirmed in using the SEA method [7], a
novel drug prediction method based on similarity analysis. 9 pairs
of aminergic GPCRs were identified by SLAP (pv0:05); 1 pair
was not decided (pw0:05); the rest of GPCRs have no mappings in
the network (the drug was not found in the network), while only
one of eight cross-boundary targets was identified by SLAP (see
Table S4), indicating that, SLAP is not capable of finding
surprising pairs (cross-boundary targets). For example, Vadilex, an
ion channel drug was predicted in SEA as a ligand of a
transporter, a totally different target, but was not identified by
SLAP. Nevertheless, SLAP performs considerably well among
GPCRs in this case.
In addition, we examined drug target pairs from MATADOR
[35] which serves as an external dataset for validation. 1065 direct
pairs were collected, of which 444 pairings are not represented in
our network. 560 out of 621 known pairs and 170 out of 444
unknown drug target pairs were identified by SLAP (pv0:05).
Comparison with Connectivity Maps
By calculating association scores across multiple targets, SLAP
can be used to build a polypharmacology profile of a drug even
when a full data matrix is not available from drug-target
experiments. We took all the 164 small molecules from the
Connectivity Map (CMap), an online dataset mapping relation-
ships of disease profiles to known drugs [18], and 113 molecules
that were mapped to our network were used to build a library. The
Figure 1. SLAP pipeline. An ontology is used to annotate public data sets and integrate them into a semantic linked network. Two nodes are
linked by one or more number of paths, but only a small number of significant paths are kept for association estimation. The path significance and
drug target associations are assessed by statistical models derived from random samples.
doi:10.1371/journal.pcbi.1002574.g001
Drug Target Association with Semantic Linked Data
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association scores of these compounds against 1683 targets were
calculated, yielding a 113|1683 score matrix. The targets of
which max score is smaller than 113 (pv0:01) were eliminated so
that each remaining protein is a target of at least one drug. After
this filtering, a matrix composed by 113 compounds and 679
targets was built. We used the signature of a given drug to
compare it with all the compounds in the library to find the most
similar drugs according to Pearson correlation coefficient.
Following the CMap approach, 8 queries including 2 HDAC
inhibitors, 1 estrogen and 5 Phenothiazines were created and the
similar pairs are listed in Table S5. We set 0.75 as threshold. 21
pairs were identified by SLAP, 19 out of 21 pairs were actually the
pairs identified by CMap. SLAP recovered all HDAC inhibitors,
but missed two hits (Genistein and Tamoxifen) for estrogen,
Figure 2. Paths between Troglitazone (label as PubChem ID: 5591) and PPARG with length lƒ3. The nodes and edges are colored by
their classes and edge types respectively. Some nodes are annotated additionally to help understand.
doi:10.1371/journal.pcbi.1002574.g002
Table 1. Path pattern examples.
Path patterns AUROC
Chemical/Drug–bind–Target–bind–Chemical/Drug–bind–Target 0.850
Chemical/Drug–bind–Target–hasGo–GO–hasGO–Target 0.824
Chemical/Drug–hasSubstructure–SubStructure–hasSubstructure–Chemical/Drug–bind–Target 0.620
Chemical/Drug–express–Target–hasPathway–Pathway–hasPathway–Target 0.495
Chemical/Drug–express–Target–hasTissue–Tissue–hasTissue–Target 0.501
Chemical/Drug–express–Target–PPI–Target 0.501
Edge types are presented as italic. AUROC shows the performance of predicting drug target interaction with the pattern alone. The first three patterns are more
informative than the last three in their capability to contribute to the associations.
doi:10.1371/journal.pcbi.1002574.t001
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however, both hits rank very high. Two Phenothiazines were not
recovered using this similarity threshold, but they are quite similar
to other three Phenothiazines compared to the remaining
compounds in the library. The results show that most of hits
identified by SLAP are true positive, indicating that the profiles
derived from SLAP resemble gene expression profiles being used
for target identification.
Assessing drug similarity from biological function
We took 157 drugs from 10 disease areas to determine whether
SLAP is able to distinguish drugs from different therapeutic areas.
For each drug, we ran SLAP against 1683 human targets and got an
association score for each drug target pair, creating a 157|1683
score matrix. We only kept the drugs and targets in which the max
score is at least larger than 113 (pv0:01) to make sure each drug has
at least one valid target and each target has at least one valid drug.
The matrix was then reduced to 147|339, followed by the
correlation calculation of every drug pairs. Only pairs with
coefficient rw0:9 were taken to build a network (see methods).
Identifying mechanisms of action. Drugs with the same
therapeutic indication tend to cluster together (Figure 5), and we
also found that these subcluster by mechanism of action. For
example, hypertension drugs, subcluster into ACE inhibitors,
thiazide-based diuretics, angiotensin II antagonists, alpha-adreno-
receptor antagonists and beta blockers (clusters 1–5 in Figure 5
respectively).
Calculating similarity of drugs by biological
function. Mostly, chemically similar drugs have similar biolog-
ical function. However, small changes of structure may also result
in big change of function, or even totally different indications. For
example, adding a methyl group to Levodopa, a dopaminergic
agent for Parkinson’s disease, makes it Methyldopa, an antia-
drenergic (Tanimoto coefficient = 0.89; Figure S6b) for antihyper-
tension. They are distinguished by SLAP (similarity TCv0:3).
The antihypertensive effect of Methyldopa is likely due to its
metabolism to alpha-methylnorepinephrine (CID:3917). SLAP is
still able to distinguish its metabolite from Levodopa (similarity
TC~0:23). Conversely, biologically similar drugs identified by
SLAP are not necessarily structural similar. For example, a
number of drugs treating insomnia are quite different in term of
structure(Figure S6a), but they are clustered together by SLAP.
Figure 3. Logarithmic association score distribution of drug target pairs.
doi:10.1371/journal.pcbi.1002574.g003
Drug Target Association with Semantic Linked Data
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Drug repurposing. Some drugs with very different indications
are clustered together. This may suggest some new indications of
drugs or possible side effect considerations. For example, Butalbital, a
Barbiturate used to treat Migraines, is clustered with nine Insomnia
drugs, two of which (Butibarbital and SecoBarbital) are Barbiturates.
Barbiturates act as central nervous system depressants, capable of
producing all levels of CNS mood alteration including Insomnia.
Triprolidine, an HIV drug, is first generation histamine H1 antagonist
used in allergic rhinitis (and is clustered with other rhinitis drugs).
Cycrimine is a central anticholinergic drug designed to reduce the
levels of acetylcholine in the treatment of Parkinson’s disease, while its
neighbor Carbinoxamine, used for allergic rhinitis, is likely capable of
treating mild cases of Parkinson’s disease as well (http://www.ebi.ac.
uk/chebi/searchId.do?chebiId=3398). It should be noted that since
SLAP does not differentiate positive and negative interactions
(activation or inhibition), the pairs may present opposite indication.
Phenylpropanolamine (an Alpha-1A adrenergic receptor agonist),
clustered withDoxazosin (an Alpha-1A adrenergic receptor antagonist
for treating hypertension) is known to cause severe hypertension [36].
Discussion
In this paper we demonstrate the SLAP method of association
prediction and the utility of predicting associations based on
semantic networks. The method performs extremely well in
correctly identifying known drug-target pairs in the data, has been
shown to outperform similar link prediction methods used in social
networking, and compares favorably with the established SEA
method for predicting new drug-target interactions, as well as with
the CMap method for associating drugs with changes in gene
expression levels. We introduce the use of a drug-similarity
network based on association profiles of drugs across targets, and
use these to propose potential new drug indications, although these
indications have not yet been validated experimentally.
The use of large semantically annotated datasets to identify
potential relationships from the linked data is a very new area, and
Figure 4. ROC curves among different prediction methods. Valid paths mean their z scorew0.
doi:10.1371/journal.pcbi.1002574.g004
Drug Target Association with Semantic Linked Data
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we consider this an initial work in this field. There are several
limitations to our current version. First, adding more data
pertaining to drugs and targets would help identify more pairs.
The side effect, disease and chemical ontology data are only linked
to a limited number of drugs at present, and protein-protein
interaction and protein pathway mapping data should greatly
enhance its utility. In particular, the ability to embed compounds
into the network for which there is no public information using
chemical structure similarity, or new targets into the network using
sequence similarity, would enable predictions to be made (albeit
more indirectly) for newly synthesized or resolved compounds and
targets. Second, as the complexity of path finding increases
dramatically with increasing path length, only shortest paths with
length lƒ3 was considered, thus potentially missing important
path patterns that have a greater path length. Third, edge weights
are defined with the assumption that the probability from one
node to its neighbors with same semantic type (e.g., from one drug
to its targets) is equal. An important limitation of our current
algorithm is that it does not enable differentiation of relationships
other than categorical ones defined in the ontology. For instance,
binding affinity could be used to weight the edge between drug
and target, the edge with lower affinity is expected to have higher
probability than that with higher affinity (or inactive interaction).
Using such data brings up the issue of comparability between
datasets: some chemogenomics datasets such as DrugBank
currently do not provide sufficient binding affinities, but the
weighting schema can be modified straightforwardly in SLAP once
the data is provided. In addition, binding types (agonist/
antagonist, activator/inhibitor) can be incorporated to classify
and weight edges. Fourth, it should be pointed out that using large
Figure 5. Drug similarity network. Each node presents a drug, and two nodes are linked if their similarity (in terms of polypharmacology profile)
rw0:9. The drugs are colored by their therapeutic indication. Five hypertension related clusters are shadowed.
doi:10.1371/journal.pcbi.1002574.g005
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public integrated datasets means there is often a fuzziness between
‘‘no data’’ and ‘‘inactive data’’: i.e. we cannot assume that because
two items do not have a relationship in the dataset, that they are
not related - for instance that a drug cannot inhibit a target.
A key question in employing any drug-target predictionmethod is
the extent to which it requires data completeness - in the extreme a
full experimental matrix - to work properly (i.e. if it needs to be
trained with consistent known active/inactive information for all
compounds against all targets). Our methods does not require such
training, indeed its purpose is to suggest potential ‘‘missing links’’ in
incomplete data. However, it should be pointed out that the level of
data completeness in a set will affect the path lengths, z-scores and
associations scores produced. We believe that overall SLAP should
be considered a useful tool for predicting that a relationship exists
between drugs and targets, and thus as a tool primarily for ideas
generation and for suggesting relationships to be probed experi-
mentally: its purpose is to predict a relationship, not necessarily
indicating a strong physical interaction. We believe it is also useful,
as demonstrated in our drug network, for profiling compounds by
their target associations (and vice versa) and we plan to explore
other types of network that can be derived from SLAP.
Many drug target prediction methods only employ single kinds
of information or relationship (e.g., substructure, side effect, etc.),
these methods are limited due to incompleteness of the data, for
instance drug target relation are far from complete [37]. The
employment of various data information can compensate for the
lack of completeness of individual information. SLAP shows a
direction to leverage such information for drug target prediction.
Several sample pairs along with their key information are listed in
Table S3. For instance, the association between pyridoxal
phosphate (CID: 1051) and cysteine conjugate-beta lyase 2
(CCBL2) is very strong (p-value = 1.9E-3), but if we removed
gene ontology information, their association would become very
weak (p-value = 0.02); the association between Dexamethasone
(CID:5743) and annexin A1(ANXA1) would hardly be captured if
substructure information were not considered.
The most compelling advantage of SLAP is its consideration of
relations from a system level rather than just by known binding
affinity data. Other than direct drug target interactions, SLAP is
also capable of recognizing indirect interactions (e.g., the change
of gene expression level) from random pairs, although the
association scores are often smaller than direct interactions (Figure
S3). It thus allows us to evaluate drug similarity based on the
biological function. The network demonstrates that such similarity
measurements not only is able to identify the drug action modes
but also could suggest the new use of drugs.
Materials and Methods
Network building
We extracted drug-target interactions and the data contributing
to either the similarity of compounds, the similarity of targets or
chemical target interaction from the Chem2Bio2RDF set [24],
and added semantic annotations using the Chem2Bio2OWL
ontology [31], to create a semantic drug-target network. For
example, two compounds are similar if they share same side
effects, same substructures or same chemical ontology terms; two
targets are similar if they share the same gene ontology terms or
ligands, or they function in the same pathway. Ten classes of
entities and 12 link types were defined in Table S1 and Table S2
respectively. A link between a drug and a target via bind type is
established if there is a binding affinity smaller than 30 um if
exists. Each node in the network is an instance of one of the
classes. The detailed information on the collection of individual
nodes and edges are in the supporting Text S1.
Drug target pairs preparation
Drug target pairs from DrugBank were used to build the
network. We took only the pairs in which drugs were small
molecules (by mapping to PubChem) and targets are Homo
sapiens (by mapping to HGNC). A total of 5607 pairs were
extracted from the network as one benchmark dataset for model
evaluation. The drug target pairs were grouped into 6 classes
according to ChEMBL [38] target classification (i.e., enzyme
(2393 pairs), membrane receptor(862 pairs), ion channel(392
pairs), transporter(209 pairs), transcription factor (208 pairs) and
others (1543 pairs)). Another benchmark dataset was created from
MATADOR [35] which was not used for network building. We
took drug target pairs with direct interaction types and confidence
scorew800 from MATADOR. 1176 direct pairs in MATADOR
were used, in which 1065 pairs have at least one path with length
lƒ3. 3665 indirect pairs in MATADOR were also extracted for
evaluating indirect drug target interaction. Indirect interactions
are caused by many different mechanisms, such as binding with
drug metabolites or changing gene expressions [35].
Path finding
A heap-based Dijkstra algorithm was employed to quickly find
the paths between two nodes [39,40]. It can achieve a complexity of
O(nlogn). Each path is represented as:
node 1{edge 1{node 2{edge 2{   {node n. The length of a
path is the number of edges between two nodes. We only took the
paths of length lƒ3. Only significant paths (assessed by statistical
models) are visualized in Cytoscape [41].
Path association
Let graph as G(V ,E), Pl(s?t) as the lth shortest path from
node s to t. ei?j as the edge from node i to node j. Ri,j as the link
(relation) type of ei,j .
It is assumed that it has an equal probability traversing node i to
its neighbor node j within the same type, thus:
p(e(i?j))~
1
Pn~1
k Ri,n~~Ri,j
where k is the degree of node i.
As the probability of each edge is independent, the probability
traversing from s to t via a path is:
p(Pl(s?t))~p(Pl(e1?2,e2?3,:::,em{1?m))~ P
m{1
i~1
p(ei?iz1)
where m is the number of nodes in the path. Since p is very small,
the logarithm is applied,
log(p(Pl(s?t)))~
Xm{1
i~1
log(p(ei?iz1))
Accordingly, the probability traversing from t to s via a path is:
p(Pl(t?s))~p(Pl(em?m{1,:::,e3?2,e2?1))~ P
m{1
i~1
p(eiz1?i)
Drug Target Association with Semantic Linked Data
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log(p(Pl(t?s)))~
Xm{1
i~1
log(p(eiz1?i))
We consider the graph as undirected, then we take the average
as the raw score of path l between s and t:
log(p(Pl(s,t)))~(log(p(Pl(s?t)))zlog(p(Pl(t?s))))=2
Statistical model
We randomly sampled 100,000 drug target pairs from
DrugBank covering 1355 approved small molecular drugs and
1683 human targets, 54,414 pairs have at least one shortest path
with length lƒ3. The sampling yielded 2,344,026 paths, which
were categorized into 34 path patterns. The scores of each pattern
were fitted to a normal distribution (Figure S1) and the expected
mean and standard deviation were estimated, followed by
calculation of the z score of every path. Only the paths with z
score greater than 0 were considered as the valid paths
contributing to the association. The z scores of all the valid paths
from s to t were summed up to get its association score, which was
later used to measure the strength of the association.
raw score(s,t)~
Xn
l
log(p(Pl)){h(log(Pl))
s(log(Pl))
where log(p(log(Pl)))wh(log(Pl)); n is the number of shortest
paths between the nodes s and t; h(log(Pl)) and s(log(Pl)) are
expected mean, expected standard deviation of the pattern to
which Pl belongs.
Some patterns may be not helpful or even noisy for assessing
drug target association. We built a test set consisting of drug target
pairs from DrugBank and the same number of random drug target
pairs sampled from the set of drugs and targets composing the real
drug target pairs. For one pair, raw scores of all the paths within a
path pattern were calculated and summed up as a score for that
path pattern. The scores were then used to rank the pairs in the
test set. The evaluation of each pattern was performed using the
area under ROC. We also applied the same procedure to the
direct pairs from MATADOR. The patterns with low ROC
(AUROCv0:51) were considered as uninformative. The unin-
formative patterns agreed by both test sets taken from DrugBank
and MATADOR were removed.
The logarithmic association scores of random pairs conforms to
a normal distribution (Figure S2); p-value is estimated to show the
probability of observing a given score by random chance alone.
Lower p-value indicates stronger relation between two objects.
Model evaluation
A test set was composed of a set of drug target pairs from
DrugBank and the same number of random pairs as decoys. Three
another test sets were created by increasing the number of random
pairs such that the sizes of random pairs are 4, 8 and 12 times
more than true drug target pairs. For each pair, the paths
including the direct link if exists were removed, and the z scores of
all valid paths were summed up as association score. The scores
were ranked to generate ROC curves [42], which are widely
adopted to measure drug target prediction methods [20,22,33,43].
We also considered Precision and Recall (PR) curve, which shows
the ratio of true positives among all the predicted positives under a
given recall rate [44]. PR curve is more informative and
biologically meaningful while the dataset is imbalanced. The
same procedure was also applied to another dataset collected from
MATADOR. Other than using SLAP scores, we considered the
number of shortest paths (maximum length 3), the number of valid
paths (significant path defined in the model), the sum of raw score
of all paths, the max raw score among all paths, and the average
raw score of all paths. In addition, we took the pairs validated in
experiments in a recent published paper [7] as novel pairs, after
manually mapping their drugs and targets to PubChem CIDs and
gene symbols, we ran SLAP to get p-values of all the valid pairs.
Assess drug similarity
We identified drug-disease pairs from Yildirim et al. [45], then
mapped the drugs to PubChem CIDs (the default compound
identifier in the network). Many drugs have multiple indications,
so in order to visualize drugs by therapeutic indications, only drugs
with one indication were kept. We also only kept the top 10
diseases ordered by the number of related drugs. The association
scores of all mapped drugs against a set of human targets construct
biological signatures which were later used for measuring drug
similarity using Pearson correlation coefficient. The pairs with
coefficient rw0:9 constitute the network. Drug structural similar-
ity was measured by Tanimoto coefficient using MACCS
fingerprint.
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